Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of IgA nephropathy recurrence after kidney transplantation: ATG-Fresenius versus basiliximab induction
2009-018189-36Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in IgA nephropathy (IgAN) and chronic glomerulonephritis (CGN) comparing ATG-Fresenius induction with Simulect (basiliximab) induction (2 arms). Primary endpoint: Clinico-histological recurrence of IgA nephropathy. Started Apr 2010; status: completed.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
IgA nephropathy (IgAN)chronic glomerulonephritis (CGN)
Beyond the preview
Go deeper on 2009-018189-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018189-36.